45:
253:
191:(NIHR) runs several research programmes that may be viewed as falling into the realm of Health Technology Assessment. Of particular note is the NIHR Health Technology Assessment programme, its longest running, which undertakes both conventional HTA in the form of Evidence Synthesis and modelling, and evidence generation with a large portfolio of pragmatic
44:
114:
and national health systems, in which case HTAs should include benefit-harm assessment and economic evaluation." And "a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent,
227:
have issued specific regional laws or regulations to manage HTA activities and processes at regional level: Abruzzo, Basilicata, Emilia-Romagna, Lazio, Liguria, Lombardia, Piemonte, Puglia, Sicilia, Toscana, and Veneto. In another four regions (Calabria, Marche, Umbria, and Valle D'Aosta) and in the
206:
Also in the UK, the
Multidisciplinary Assessment of Technology Centre for Healthcare carries out HTA in collaboration with the health service, the NHS and various industrial partners. MATCH is organised into four themes addressing key HTA topics including Health Economics, Tools for Industry, User
165:
The discipline of HTA was first developed in the U.S. Office of
Technology Assessment, which published its first report in 1976. The growth of HTA internationally can be seen in the expanding membership of the International Network of Agencies for Health Technology Assessment (INAHTA), a non-profit
292:
A recent study explored the implementation of HTA in three middle-income countries (MICs) and its influence on health system objectives. The study investigated the impact of HTA globally through a systematic literature review. The study also surveyed stakeholders from the middle-income countries.
131:
Health technology assessment is intended to provide a bridge between the world of research and the world of decision-making. HTA is an active field internationally and has seen continued growth fostered by the need to support management, clinical, and policy decisions. It has also been advanced by
296:
The results indicated that the benefits of HTA implementation in these countries largely outweigh the drawbacks. The major advantages identified include enhanced transparency and accountability in healthcare decisions, leading to more informed and equitable healthcare policies.
314:
It was also noted that HTA's influence extends to the broader health system goals, such as health gain, equity in health, and responsiveness to patient needs. However, the impact on direct health gains and financial protection of households is less pronounced.
1405:
155:
Any intervention that may be used to promote health, to prevent, diagnose or treat disease or for rehabilitation or long-term care. This includes the pharmaceuticals, devices, procedures and organizational systems used in health
110:
of the use of health technologies. The precise balance of these inputs depends on the purpose of each individual HTA. A major use of HTAs is in informing reimbursement and coverage decisions by
926:
982:
Fasseeh, Ahmad Nader; Saragih, Sarah Maria; Hayek, Noha; Brodovska, Sasha; Ismail, Adham; ElShalakani, Amr; Abaza, Sherif; Obeng, George Dennis; Ameyaw, David; Kalo, Zoltan (2022-12-01).
166:
umbrella organization established in 1993. Organizations and individuals involved in the production of HTA publications may also affiliated with international societies such as
1385:
1400:
1390:
1071:
734:
Lehoux, Pascale; Battista, Renaldo N.; Granados, Alicia; Gallo, Pedro; Tailliez, Stéphanie; Coyle, Doug; Marchetti, Marco; Borgia, Piero; Ricciardi, Gualtiero (2005).
310:
Economic impact: While HTA can generate cost savings in specific areas, its overall impact on the fiscal sustainability of healthcare systems in MICs remains unclear.
839:
1175:
1150:
188:
958:
807:
307:
Enhanced transparency and accountability: The most evident benefit of HTA is its role in improving the clarity and responsibility of healthcare decisions.
1380:
144:
from making wrong decisions continue to grow. HTA is now also used in assessment of innovative medical technologies like telemedicine e.g. by use of the
107:
918:
868:
200:
31:
1395:
1064:
596:
1426:
145:
119:
that are patient focused and seek to achieve best value. Despite its policy goals, HTA must always be firmly rooted in research and the
304:
Improved decision making: HTA aids in making better health financing decisions, including resource allocation and policy formulation.
1410:
1057:
167:
1482:
263:
95:). The purpose of HTA is to inform "decision-making in order to promote an equitable, efficient, and high-quality health system
1477:
736:"International Master's Program in health technology assessment and management: assessment of the first edition (2001--2003)"
215:
Canada also has a health technology assessment body called the
Canadian Agency for Drugs and Technologies in Health (CADTH).
174:(ISPOR). Academic courses, typically in Masters programs, are also offered in health technology assessment and management.
1160:
831:
106:
that considers evidence regarding clinical effectiveness, safety, cost-effectiveness and, when broadly applied, includes
1290:
947:
273:
779:
59:) is a multidisciplinary process that uses systematic and explicit methods to evaluate the properties and effects of a
1472:
1249:
1125:
192:
519:
318:
The study emphasizes the gradual adoption of HTA in MICs and the necessity for continuous assessment of its impact.
1467:
1185:
1145:
1200:
1195:
1155:
1120:
236:
800:
1269:
1140:
1130:
1354:
1180:
1165:
1094:
1080:
919:"HTA in Italy: results from the national survey by Agenas and SIHTA. Read English summary produced by MTRC"
232:
of
Bolzano and Trento, HTA is performed at different levels, even if no legislation has yet been produced.
1364:
1359:
1321:
1170:
1220:
1190:
1135:
1099:
133:
984:"Impact of health technology assessment implementation with a special focus on middle-income countries"
860:
983:
446:
417:
38:
948:"Countries with National agency/unit/committee that produces HTA reports for the Ministry of Health"
1349:
897:
712:
618:
O'Rourke, Brian; Oortwijn, Wija; Schuller, Tara; the
International Joint Task Group (13 May 2020).
269:
229:
88:
84:
72:
1115:
771:
657:
592:
573:
391:
620:"The new definition of health technology assessment: A milestone in international collaboration"
354:"The new definition of health technology assessment: A milestone in international collaboration"
683:
1274:
1234:
1013:
763:
755:
649:
641:
565:
498:
383:
375:
332:
120:
103:
80:
60:
300:
The study has shown that HTA has a positive impact on several aspects of healthcare systems:
1003:
995:
747:
631:
591:
INAHTA (International
Network of Agencies for Health Technology Assessment). (Oct 8, 2013).
557:
488:
480:
365:
327:
224:
141:
137:
111:
17:
1306:
1279:
1244:
523:
116:
548:
Menon D.; Marshall, D (1996). "The internationalization of heath technology assessment".
1406:
Swedish Agency for Health
Technology Assessment and Assessment of Social Services (SBU)
1326:
1264:
1229:
493:
468:
68:
1461:
1316:
1311:
1239:
661:
484:
395:
92:
775:
1259:
1205:
577:
196:
64:
132:
the evolution of evaluative methods in the social and applied sciences, including
115:
unbiased, robust manner. Its aim is to inform the formulation of safe, effective,
1442:
1285:
1210:
999:
751:
636:
619:
561:
370:
353:
1017:
759:
645:
379:
735:
1040:
International
Network of Agencies for Health Technology Assessment (INAHTA)
767:
653:
502:
387:
1049:
569:
516:
801:"A Tale of Two University-Based Health Technology Assessment Initiatives"
439:"The International Network of Agencies for Health Technology Assessment"
410:"The International Network of Agencies for Health Technology Assessment"
239:
provides an overview of countries and their corresponding HTA agencies.
1008:
76:
140:. Health policy decisions are becoming increasingly important as the
199:. The programme's research is regularly published in NIHR's journal
705:"International Society for Pharmacoeconomics and Outcomes Research"
171:
172:
International
Society for Pharmacoeconomics and Outcomes Research
1053:
246:
740:
International
Journal of Technology Assessment in Health Care
624:
International Journal of Technology Assessment in Health Care
550:
International Journal of Technology Assessment in Health Care
515:
EUnetHTA (European network for Health Technology Assessment)
358:
International Journal of Technology Assessment in Health Care
352:
O'Rourke, Brian; Oortwijn, Wija; Schuller, Tara (June 2020).
1386:
Canadian Agency for Drugs and Technologies in Health (CADTH)
1045:
European Network for Health Technology Assessment (EUnetHTA)
1044:
438:
409:
704:
1401:
National Institute for Health and Care Excellence (NICE)
1039:
889:
1034:
63:. Health technology is conceived as any intervention (
675:
1435:
1419:
1373:
1342:
1335:
1299:
1219:
1108:
1087:
676:"Health Technology Assessment International (HTAi)"
1381:Agency for Healthcare Research and Quality (AHRQ)
1035:Health Technology Assessment International (HTAi)
102:It has other definitions including "a method of
1176:Evidence-based pharmacy in developing countries
1151:Evidence-based library and information practice
189:National Institute for Health and Care Research
153:
1411:WHO Evidence-Informed Policy Network (EVIPNet)
1065:
469:". EBM, HTA, and CER: clearing the confusion"
151:Health technology can be defined broadly as:
8:
1396:German Agency for Quality in Medicine (AEZQ)
266:to a single study focused on three countries
1339:
1072:
1058:
1050:
276:this issue before removing this message.
168:Health Technology Assessment International
1007:
635:
492:
369:
207:Needs and Procurement and Supply chain.
43:
536:The scientific basis of health services
517:https://www.eunethta.eu/about-eunethta/
344:
836:National Institute for Health Research
715:from the original on 10 September 2019
599:from the original on February 21, 2014
32:Health Technology Assessment (journal)
7:
1427:Centre for Reviews and Dissemination
146:Model for assessment of telemedicine
91:, regulatory approval, post-market,
270:create a more balanced presentation
108:social, ethical, and legal aspects
25:
923:Med Tech Reimbursement Consulting
87:) at any point in its lifecycle (
485:10.1111/j.1468-0009.2010.00598.x
251:
964:from the original on 2024-02-03
929:from the original on 2021-06-27
900:from the original on 2019-12-14
871:from the original on 2022-01-10
842:from the original on 2022-01-10
813:from the original on 2014-10-19
782:from the original on 2021-10-27
686:from the original on 2022-01-19
449:from the original on 2021-10-27
420:from the original on 2021-10-27
832:"Health Technology Assessment"
1:
1161:Evidence-based medical ethics
538:. BMJ Publishing Group, 1996.
467:Luce BR, et al. (2010).
37:For other uses of "HTA", see
1291:Policy-based evidence making
1255:Health technology assessment
988:Health Policy and Technology
243:Impact of HTA implementation
201:Health Technology Assessment
53:Health technology assessment
18:Health Technology Assessment
1250:Randomized controlled trial
1126:Evidence-based conservation
48:HTA conference and workshop
1499:
1186:Evidence-based prosecution
1146:Evidence-based legislation
1000:10.1016/j.hlpt.2022.100688
36:
29:
1201:Evidence-based toxicology
1196:Evidence-based scheduling
1156:Evidence-based management
1121:Evidence-based assessment
752:10.1017/s0266462305050130
637:10.1017/S0266462320000215
562:10.1017/S0266462300009375
371:10.1017/S0266462320000215
237:World Health Organization
1270:Pragmatic clinical trial
1141:Evidence-based education
1131:Evidence-based dentistry
223:As of today, 11 Italian
27:Field of policy analysis
1181:Evidence-based policing
1166:Evidence-based medicine
1095:Evidence-based practice
1081:Evidence-based practice
861:"About the HTA journal"
1483:Life sciences industry
1365:Science-Based Medicine
1360:Campbell Collaboration
1355:Cochrane Collaboration
1171:Evidence-based nursing
158:
49:
1478:Technology assessment
1191:Evidence-based policy
1136:Evidence-based design
1100:Hierarchy of evidence
865:NIHR Journals Library
187:The United Kingdom's
134:clinical epidemiology
47:
30:For the journal, see
230:autonomous provinces
39:HTA (disambiguation)
1350:James Lind Alliance
1473:Medical technology
1116:Effective altruism
522:2021-01-17 at the
104:evidence synthesis
50:
1468:Impact assessment
1455:
1454:
1451:
1450:
1275:Spaced repetition
1235:Systematic review
333:Pharmacoeconomics
290:
289:
268:. Please help to
260:This section may
142:opportunity costs
121:scientific method
61:health technology
16:(Redirected from
1490:
1340:
1074:
1067:
1060:
1051:
1022:
1021:
1011:
979:
973:
972:
970:
969:
963:
952:
944:
938:
937:
935:
934:
915:
909:
908:
906:
905:
886:
880:
879:
877:
876:
857:
851:
850:
848:
847:
828:
822:
821:
819:
818:
812:
805:
797:
791:
790:
788:
787:
731:
725:
724:
722:
720:
701:
695:
694:
692:
691:
672:
666:
665:
639:
615:
609:
608:
606:
604:
588:
582:
581:
545:
539:
532:
526:
513:
507:
506:
496:
464:
458:
457:
455:
454:
435:
429:
428:
426:
425:
406:
400:
399:
373:
349:
328:Horizon scanning
285:
282:
255:
254:
247:
138:health economics
21:
1498:
1497:
1493:
1492:
1491:
1489:
1488:
1487:
1458:
1457:
1456:
1447:
1431:
1415:
1369:
1331:
1307:Archie Cochrane
1295:
1280:Risk assessment
1245:Umbrella review
1215:
1104:
1083:
1078:
1031:
1026:
1025:
981:
980:
976:
967:
965:
961:
950:
946:
945:
941:
932:
930:
917:
916:
912:
903:
901:
890:"CADTH | CADTH"
888:
887:
883:
874:
872:
859:
858:
854:
845:
843:
830:
829:
825:
816:
814:
810:
803:
799:
798:
794:
785:
783:
733:
732:
728:
718:
716:
703:
702:
698:
689:
687:
674:
673:
669:
617:
616:
612:
602:
600:
590:
589:
585:
547:
546:
542:
533:
529:
524:Wayback Machine
514:
510:
466:
465:
461:
452:
450:
437:
436:
432:
423:
421:
408:
407:
403:
351:
350:
346:
341:
324:
286:
280:
277:
256:
252:
245:
221:
213:
185:
180:
163:
129:
117:health policies
42:
35:
28:
23:
22:
15:
12:
11:
5:
1496:
1494:
1486:
1485:
1480:
1475:
1470:
1460:
1459:
1453:
1452:
1449:
1448:
1446:
1445:
1439:
1437:
1433:
1432:
1430:
1429:
1423:
1421:
1417:
1416:
1414:
1413:
1408:
1403:
1398:
1393:
1388:
1383:
1377:
1375:
1371:
1370:
1368:
1367:
1362:
1357:
1352:
1346:
1344:
1337:
1333:
1332:
1330:
1329:
1327:John Ioannidis
1324:
1319:
1314:
1309:
1303:
1301:
1297:
1296:
1294:
1293:
1288:
1282:
1277:
1272:
1267:
1265:GRADE approach
1262:
1257:
1252:
1247:
1242:
1237:
1232:
1230:Clinical trial
1226:
1224:
1217:
1216:
1214:
1213:
1208:
1203:
1198:
1193:
1188:
1183:
1178:
1173:
1168:
1163:
1158:
1153:
1148:
1143:
1138:
1133:
1128:
1123:
1118:
1112:
1110:
1106:
1105:
1103:
1102:
1097:
1091:
1089:
1085:
1084:
1079:
1077:
1076:
1069:
1062:
1054:
1048:
1047:
1042:
1037:
1030:
1029:External links
1027:
1024:
1023:
974:
957:. 2021-04-08.
939:
910:
881:
852:
823:
792:
746:(1): 104–112.
726:
696:
667:
630:(3): 187–190.
610:
593:"HTA glossary"
583:
540:
534:Battista, RN:
527:
508:
459:
430:
401:
364:(3): 187–190.
343:
342:
340:
337:
336:
335:
330:
323:
320:
312:
311:
308:
305:
288:
287:
272:. Discuss and
259:
257:
250:
244:
241:
220:
217:
212:
209:
197:cohort studies
184:
183:United Kingdom
181:
179:
176:
162:
159:
128:
125:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1495:
1484:
1481:
1479:
1476:
1474:
1471:
1469:
1466:
1465:
1463:
1444:
1441:
1440:
1438:
1434:
1428:
1425:
1424:
1422:
1418:
1412:
1409:
1407:
1404:
1402:
1399:
1397:
1394:
1392:
1389:
1387:
1384:
1382:
1379:
1378:
1376:
1372:
1366:
1363:
1361:
1358:
1356:
1353:
1351:
1348:
1347:
1345:
1341:
1338:
1334:
1328:
1325:
1323:
1320:
1318:
1317:Iain Chalmers
1315:
1313:
1312:David Sackett
1310:
1308:
1305:
1304:
1302:
1298:
1292:
1289:
1287:
1283:
1281:
1278:
1276:
1273:
1271:
1268:
1266:
1263:
1261:
1258:
1256:
1253:
1251:
1248:
1246:
1243:
1241:
1240:Meta-analysis
1238:
1236:
1233:
1231:
1228:
1227:
1225:
1222:
1218:
1212:
1209:
1207:
1204:
1202:
1199:
1197:
1194:
1192:
1189:
1187:
1184:
1182:
1179:
1177:
1174:
1172:
1169:
1167:
1164:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1142:
1139:
1137:
1134:
1132:
1129:
1127:
1124:
1122:
1119:
1117:
1114:
1113:
1111:
1107:
1101:
1098:
1096:
1093:
1092:
1090:
1086:
1082:
1075:
1070:
1068:
1063:
1061:
1056:
1055:
1052:
1046:
1043:
1041:
1038:
1036:
1033:
1032:
1028:
1019:
1015:
1010:
1005:
1001:
997:
994:(4): 100688.
993:
989:
985:
978:
975:
960:
956:
949:
943:
940:
928:
924:
920:
914:
911:
899:
895:
891:
885:
882:
870:
866:
862:
856:
853:
841:
837:
833:
827:
824:
809:
802:
796:
793:
781:
777:
773:
769:
765:
761:
757:
753:
749:
745:
741:
737:
730:
727:
714:
710:
706:
700:
697:
685:
681:
677:
671:
668:
663:
659:
655:
651:
647:
643:
638:
633:
629:
625:
621:
614:
611:
598:
594:
587:
584:
579:
575:
571:
567:
563:
559:
555:
551:
544:
541:
537:
531:
528:
525:
521:
518:
512:
509:
504:
500:
495:
490:
486:
482:
479:(2): 256–76.
478:
474:
470:
463:
460:
448:
444:
440:
434:
431:
419:
415:
411:
405:
402:
397:
393:
389:
385:
381:
377:
372:
367:
363:
359:
355:
348:
345:
338:
334:
331:
329:
326:
325:
321:
319:
316:
309:
306:
303:
302:
301:
298:
294:
284:
281:February 2024
275:
271:
267:
265:
258:
249:
248:
242:
240:
238:
233:
231:
226:
218:
216:
210:
208:
204:
202:
198:
194:
190:
182:
177:
175:
173:
169:
160:
157:
152:
149:
147:
143:
139:
135:
126:
124:
122:
118:
113:
109:
105:
101:
98:
94:
93:disinvestment
90:
86:
82:
78:
74:
70:
66:
62:
58:
54:
46:
40:
33:
19:
1374:Governmental
1260:PICO process
1254:
1223:and concepts
1206:Journalology
1109:Applications
991:
987:
977:
966:. Retrieved
954:
942:
931:. Retrieved
922:
913:
902:. Retrieved
894:www.cadth.ca
893:
884:
873:. Retrieved
864:
855:
844:. Retrieved
835:
826:
815:. Retrieved
795:
784:. Retrieved
743:
739:
729:
717:. Retrieved
708:
699:
688:. Retrieved
679:
670:
627:
623:
613:
601:. Retrieved
586:
556:(1): 45–51.
553:
549:
543:
535:
530:
511:
476:
472:
462:
451:. Retrieved
442:
433:
422:. Retrieved
413:
404:
361:
357:
347:
317:
313:
299:
295:
291:
278:
264:undue weight
261:
234:
222:
214:
205:
186:
164:
154:
150:
130:
99:
96:
56:
52:
51:
1443:Examine.com
1286:uncertainty
1284:Scientific
1211:Metascience
1009:10831/89813
719:9 September
170:(HTAi) and
1462:Categories
1343:Non-profit
1322:Ken Harvey
968:2024-02-03
933:2021-06-27
904:2021-10-27
875:2022-01-10
846:2022-01-10
817:2021-10-27
786:2021-10-27
690:2022-01-10
603:October 8,
453:2021-10-27
424:2021-10-27
339:References
178:By country
89:pre-market
1088:Key terms
1018:2211-8837
760:0266-4623
662:218617518
646:0266-4623
473:Milbank Q
396:218617518
380:0266-4623
81:procedure
1420:Academic
1391:EUnetHTA
959:Archived
927:Archived
898:Archived
869:Archived
840:Archived
808:Archived
780:Archived
776:40682931
768:15736521
713:Archived
684:Archived
654:32398176
597:Archived
595:. HTAi.
520:Archived
503:20579285
447:Archived
418:Archived
388:32398176
322:See also
148:(MAST).
112:insurers
73:medicine
1221:Methods
578:6982793
570:8690561
494:2980346
274:resolve
225:regions
161:History
127:Purpose
85:program
77:vaccine
1336:Groups
1300:People
1016:
774:
766:
758:
660:
652:
644:
576:
568:
501:
491:
443:INAHTA
414:INAHTA
394:
386:
378:
211:Canada
100:
69:device
1436:Other
962:(PDF)
951:(PDF)
811:(PDF)
804:(PDF)
772:S2CID
709:ISPOR
658:S2CID
574:S2CID
392:S2CID
262:lend
219:Italy
156:care.
1014:ISSN
764:PMID
756:ISSN
721:2018
680:HTAi
650:PMID
642:ISSN
605:2013
566:PMID
499:PMID
384:PMID
376:ISSN
235:The
228:two
195:and
193:RCTs
136:and
65:test
1004:hdl
996:doi
955:WHO
748:doi
632:doi
558:doi
489:PMC
481:doi
366:doi
123:".
57:HTA
1464::
1012:.
1002:.
992:11
990:.
986:.
953:.
925:.
921:.
896:.
892:.
867:.
863:.
838:.
834:.
806:.
778:.
770:.
762:.
754:.
744:21
742:.
738:.
711:.
707:.
682:.
678:.
656:.
648:.
640:.
628:36
626:.
622:.
572:.
564:.
554:12
552:.
497:.
487:.
477:88
475:.
471:.
445:.
441:.
416:.
412:.
390:.
382:.
374:.
362:36
360:.
356:.
203:.
97:".
83:,
79:,
75:,
71:,
67:,
1073:e
1066:t
1059:v
1020:.
1006::
998::
971:.
936:.
907:.
878:.
849:.
820:.
789:.
750::
723:.
693:.
664:.
634::
607:.
580:.
560::
505:.
483::
456:.
427:.
398:.
368::
283:)
279:(
55:(
41:.
34:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
